This Is MS Multiple Sclerosis Community: Knowledge & Support
Welcome to the world's leading forum on Multiple Sclerosis research, support, and knowledge. For over 10 years, This is MS has provided an unbiased community dedicated to Multiple Sclerosis patients, caregivers, and affected loved ones.
Frank, sorry to report, but the anti V5.2/V5.3 mAb turned out to be ATM-027, from Astrazeneca, which failed. The first link is to a phase 2 study of the drug, the second link is an Astrazeneca document where they actually admit that they discontinued ATM-027 (unusual for a pharma co to admit failure).
Dizzy, I decided to make the list about disease-modifying therapies -ie- therapies that reduce relapses or lesions or progression etc. So things to treat symptoms haven't been covered. I think it would be good to have a separate list for symptomatic treatments though if somebody else is interested in putting one together...
dignan wrote:Napay, good question, I couldn't find any information on the trial results. It is possible they aren't ready to release them yet. Maybe the researchers would answer an email from you...
I'm on it. But, I'd like some advice. I've not done this beofre. Are these folks open to this sort of communication? Is a formal communication better? Will they be "Put out" if I'm too informal? How does one communicate to get the best likelihood of a answer from a researcher?
It would be really nice to be able to put links in here
If I have included a bad link, google the word "Scholar", click link for "Google Scholar". Search for the name of the paper and author in Google Scholar.
This site does not offer, or claim to offer, medical, legal, or professional advice.
All treatment decisions should always be made with the full knowledge of your physicians.
This is MS does not create, endorse, or republish any content.
All postings are the responsibility of the poster. All logos and trademarks in this site are property of their respective owners. All users must respect our rules for intellectual property rights.